Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors

Fineline Cube May 9, 2026
Company Drug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Fineline Cube May 9, 2026
Company Deals

Meheco’s Genertec Partners with AstraZeneca for COVID-19 Antibody Evusheld in China

Fineline Cube Jan 16, 2023

China Meheco Group Co., Ltd (SHA: 600056) announced that its subsidiary Genertec Meheco has entered...

Company Drug

Guangzhou’s Overseas Pharma Wins China Clinical Trial Approval for OPL-038

Fineline Cube Jan 16, 2023

Guangzhou-based Overseas Pharmaceuticals, Ltd has secured clinical trial approval in China for its sustained and...

Company Deals

Eyougene Raises Hundreds of Millions in Series B Funding for Expansion

Fineline Cube Jan 13, 2023

Eyougene Co., Ltd, a digital Contract Development and Manufacturing Organization (CDMO) based in Shanghai, has...

Company Deals

LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion

Fineline Cube Jan 13, 2023

Shanghai LePure Biotech Co., Ltd, a China-based biotechnology company, has reportedly raised “hundreds of millions”...

Company Deals

Shenzhen Keyto Fluid Control Secures Series C Funding for Expansion

Fineline Cube Jan 13, 2023

Shenzhen Keyto Fluid Control Co., Ltd, a China-based manufacturer of precision fluid control components, has...

Company Drug

Xinhua Pharma’s OAB-14 Receives NMPA Approval for Phase I Alzheimer’s Study

Fineline Cube Jan 13, 2023

China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) has announced receiving approval from the National...

Company Deals

Cii Tech Secures Tens of Millions in Pre-Series A Funding for Mass Spectrometry

Fineline Cube Jan 13, 2023

China Innovation Instrument (Cii Tech), a life sciences instrument maker based in Ningbo, has reportedly...

Company Deals

TechnoDerma Raises Series A+ Funding to Advance Dermatology Pipeline

Fineline Cube Jan 13, 2023

TechnoDerma Medicines Inc., a Zhejiang-based developer of dermatology small molecules, has reportedly raised “tens of...

Company Drug

Konruns’ KC1036 Advances to Phase II Study for Lung Adenocarcinoma

Fineline Cube Jan 13, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced receiving approval from the National Medical...

Company Drug

Harbour BioMed’s HBM1020 Receives FDA Approval for US Phase I Study

Fineline Cube Jan 13, 2023

Harbour BioMed (HKG: 2142), a global biotech company operating in the Netherlands, the United States,...

Company

Porton Pharma Solutions to Invest EUR 50 Million in Slovenia Bio-Industry Park

Fineline Cube Jan 13, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions is set to establish a...

Company Digital

ClouDr Partners with Shaanxi Pharmaceutical Firms for Integrated Healthcare Solutions

Fineline Cube Jan 13, 2023

Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), better known as “ClouDr,” has announced...

Company Deals

Syneos Health Partners with Fosun Pharma to Commercialize Serplulimab in US

Fineline Cube Jan 13, 2023

US-based Syneos Health (Nasdaq: SYNH) has revealed a strategic partnership with Fosun Pharma USA Inc.,...

Company Drug

Sanofi’s iGlarLixi Approved in China for Type 2 Diabetes Management

Fineline Cube Jan 13, 2023

French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that the National Medical Products Administration (NMPA)...

Company Drug

Roche’s Polivy Approved by China’s NMPA for Lymphoma Treatment

Fineline Cube Jan 13, 2023

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that the National Medical Products...

Policy / Regulatory

China Launches Eighth Round of National Volume-Based Procurement for 41 Drugs

Fineline Cube Jan 13, 2023

The National Healthcare Security Administration has issued a notice to initiate the COVID-delayed eighth round...

Company

Med Vision Secures A+ Round Financing to Accelerate Digital Therapy Commercialization

Fineline Cube Jan 12, 2023

Hangzhou-based Med Vision Technology Co., Ltd. has successfully completed an A+ round financing, raising several...

Company Drug Legal / IP

MSD China to Take Legal Action Against Market Infringement of Molnupiravir

Fineline Cube Jan 12, 2023

Merck Sharp & Dohme (MSD, NYSE: MRK)’s China unit has issued a WeChat notification vowing...

Company Deals

Med Vision Secures Series A+ Funding to Expand Digital Therapy Portfolio

Fineline Cube Jan 12, 2023

Med Vision, a Hangzhou-based digital therapy specialist, has reportedly raised “tens of millions” of renminbi...

Company Drug

Kexing Pharmaceutical Initiates Phase I Trial for IFN-Alpha-1b Inhalation Solution

Fineline Cube Jan 12, 2023

China-based Kexing Pharmaceutical (SHA: 688136) has announced the enrollment of the first subject and dosing...

Posts pagination

1 … 570 571 572 … 662

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors
  • Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda
  • Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China
  • Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline
  • Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors

Company Drug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Company Drug

Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China

Company Drug

Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.